Urol. praxi. 2018;19(1):10-15 [Med. praxi. 2018;15(1):9-14]

Uncomplicated lower urinary tract infections in women – options of treatment and prevention

MUDr. Jiří Kladenský
UROINTEGRITAS, s. r. o., Brno

Urinary tract infections (UTIs) are among very frequent medical conditions for which women visit their general practitioner. Acuteuncomplicated cystitis the diagnosis of which is usually straightforward is the most common manifestation of UTIs in women. Whenchoosing an appropriate antimicrobial agent, it is advisable to take into consideration its pharmacokinetics, the assumed spectrumof efficacy, and the effect on the vaginal flora. Short-term treatment with a duration of three to five days is preferred. In women withrecurrent cystitides, following the commencement of appropriate therapy and retreatment of infection, it is necessary to perform acomprehensive urological evaluation in order to rule out functional or anatomical abnormalities. This almost invariably involves urineculture and targeted retreatment according to susceptibility. The review article presents differentiated options of treatment and preventionof lower urinary tract infections in women with both antimicrobial agents and lifestyle measures plus preparations not included inthe group of antimicrobial agents; however, when indicated correctly, their administration can bring long-term relief to these women.

Keywords: acute uncomplicated cystitis, recurrent cystitis, complicated urinary tract infection, asymptomatic bacteriuria

Published: March 15, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kladenský J. Uncomplicated lower urinary tract infections in women – options of treatment and prevention. Urol. praxi. 2018;19(1):10-15.
Download citation

References

  1. Nicolle LE. Managing recurrent urinary tract infections in women. Womens health (Lond Engl) 2005, 1(1): 39-50. Go to original source... Go to PubMed...
  2. Kladenský J. Infekce dolních močových cest u žen - možnosti diferencovaného přístupu léčby a prevence. Urolog. pro praxi 2010, 11(5): 238.
  3. Hooton TM. Reccurent urinary tract infection in women. Int J Antimicrob Agents 2001, 17(4): 259-268. Go to original source... Go to PubMed...
  4. European Association of Urology Guidelines 2017, Urological Infections.
  5. Hendlin D, Stapley EO, Jackson M, et al. Phosphomycin, a new antibiotic, produced by strains OF streptopmyces. Science 1969, 166(901): 122-123. Go to original source... Go to PubMed...
  6. Fajfr M, louda M, Paterová P, Ryšková L. Fosfomycin trometamol - staronové antibiotikum v urologické praxi. Urolog. pro praxi 2015, 16(4): 148-155.
  7. Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, Lavi I, Stamm W. Empiric use of trimethoprim - sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002, 34(9): 1165-1169. Go to original source... Go to PubMed...
  8. Kladenský J, Toršová V, Chmelařová E. Přínos nifuratelu pro léčbu akutních nekomplikovaných uroinfekcí. Urologie pro praxi 2006, 7: 109-110.
  9. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Rezistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008, 54(5): 1164-1175. Go to original source... Go to PubMed...
  10. Finger G, Landau D. Pathogenesis of urinary tract infections with normal female anatomy. Lancet Infect Dis 2004, 4(10): 631-635. Go to original source... Go to PubMed...
  11. Bartoníčková K. Uroinfekce, Praha: Galén 2000: 43-49.
  12. Gupta K, Chou M, Howell A, Wobbe C, Grady R, Stapteton A. Cranberry products inhibit adherence of P-fimbriated E. coli to ptimary cultured bladder and vaginal epithepial cells. J Urol 2007, 177(6): 2357-2360. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.